Similarly, dyskerin overexpression has been observed in breast and prostate cancers (Kan et al., 2021; Stockert et al., 2019), whereas reduced levels are associated with breast and endometrial cancer progression (Alnafakh et al., 2021; Zacchini et al., 2022). Here, DKC1 is linked to prostate cancer.